Codeine addiction is opioid addiction, and it is treated as one.
Codeine is a prescription and pharmacy opioid that the body converts into morphine. Regular use builds tolerance and dependence the same way stronger opioids do, and combination products add risks people rarely see coming. Jintara treats codeine dependence under the same psychiatrist-led opioid addiction treatment protocol used for heroin and prescription painkillers.
Fully Licensed and Hospital Accredited
Codeine Is an Opioid That Becomes Morphine in the Body.
Codeine is an opioid. It is prescribed for pain and cough, sold in combination tablets, and in some countries has been available from a pharmacy without a prescription. That accessibility is exactly why codeine dependence is so easy to miss. It does not look like the popular picture of opioid addiction, yet it acts on the same receptors.
- It works by becoming morphine: Codeine has little effect on its own. The liver converts it into morphine, so codeine dependence is morphine dependence at the receptor level, and the withdrawal is an opioid withdrawal.
- Dependence looks ordinary: A person taking codeine daily for a persistent cough or ongoing pain can cross from use into dependence without ever buying anything illegal.
- Treated as opioid use disorder: Jintara treats codeine presentations under its opioid protocol, beginning with a full psychiatric assessment on admission and, where needed, a supervised medical detox.
The starting substance does not change the clinical mechanism, and the clinical mechanism is what the treatment is built around.
Codeine Dependence Is Common and Usually Starts Legally.
Codeine dependence is not a fringe problem. In Australia, where codeine analgesics were sold over the counter until 2018, those products accounted for a large share of community opioid purchases, and codeine-related deaths roughly doubled over the 2000s. When the country moved codeine to prescription-only, low-dose supply fell sharply and poison-centre calls dropped by about half, which shows how much dependence the easy access had been feeding. NIDA on prescription drug misuse documents the same pattern across prescription opioids.
- It usually starts with a prescription: Many people begin after surgery, injury, or a long illness. Others start with an over-the-counter product where it is permitted, then find the same dose stops working.
- The path is slow and medical: Codeine dependence tends to develop quietly and legally, which is why it carries so little stigma and so much delay before anyone seeks help. Many first identify it as prescription drug addiction.
- Australia and the UK see it most: Codeine has been more widely prescribed and historically more widely sold without a script in both countries. Jintara treats a significant number of clients from each.
The people who develop codeine dependence are often not who families expect, and the ordinary route in is exactly what makes it hard to spot.
FDA Drug Safety
Acetaminophen overdose causes roughly half of acute liver failure cases in the United States, and much of that is unintentional, from people taking more of a combination product than they realise. The FDA limited prescription combination products to 325 milligrams of acetaminophen per dose and added a boxed warning for severe liver failure, with the adult daily ceiling set at 4,000 milligrams.
Source: FDA. Acetaminophen Information and 325 mg Dosage Limit
Combination Codeine Products Add a Hidden Liver Risk.
Most codeine is not sold as codeine alone. It is combined with paracetamol, known as acetaminophen, in products like co-codamol and Tylenol with codeine. This creates a danger pure codeine does not: as a person escalates the dose to chase the opioid effect, they also escalate their paracetamol intake, and paracetamol is toxic to the liver in overdose.
- Two risks hidden in one tablet: The opioid drives the escalation, and the paracetamol quietly climbs with it. The NIH LiverTox resource documents that some of the most serious accidental overdoses occur in people taking combination products containing codeine.
- Arrival can mean liver stress: A client dependent on a codeine-paracetamol combination may present with liver strain that pure-codeine use would not produce.
- Screened on admission: Jintara's clinical intake maps the exact formulation used, and the day-two hospital workup exists to catch organ effects before the taper is finalised.
Codeine dependence rarely comes with a warning label, and combination products hide two problems where most people see one.
FDA Boxed Warning
The FDA restricted codeine with a boxed warning because ultra-rapid metabolisers can suffer life-threatening respiratory depression at ordinary doses. Codeine is contraindicated in children under 12 and after tonsillectomy or adenoidectomy in under-18s. For adults in treatment, the same variation is why a codeine taper must be individualised rather than run from a generic chart.
Why the Same Codeine Dose Affects People Differently.
Two people can take the identical codeine dose and have completely different experiences, and the reason is genetic. Codeine is converted to morphine by a liver enzyme called CYP2D6, and people carry different versions of the gene that makes it. The NIH genetics summary on codeine and CYP2D6 explains that ultra-rapid metabolisers convert codeine to morphine faster and more completely, so an ordinary dose can produce a far larger opioid effect, and a far larger dependence risk, than the label suggests.
- Ultra-rapid metabolisers: They convert more codeine to morphine, feel a stronger effect at a standard dose, and carry a higher dependence risk that neither they nor the prescriber usually anticipates.
- Poor metabolisers: They convert very little, feel less effect, and may push the dose up in search of relief, which raises their exposure to the paracetamol in combination products.
- The standard dose is often the wrong dose: For a meaningful share of people, the labelled dose does not match their metabolism, which is why Jintara's psychiatrist sets the taper against the individual.
This genetic variation is one reason codeine is less predictable than it looks, and why a taper cannot be run from a fixed schedule.
How Codeine Withdrawal Compares to Heroin Withdrawal.
Codeine is a short-acting opioid, so its withdrawal follows the same shape as heroin withdrawal rather than a milder curve. Symptoms typically begin 8 to 24 hours after the last dose and run for roughly 4 to 10 days, with the familiar cluster of muscle aches, restlessness, sweating, nausea, insomnia, and craving. NIDA's opioid research sets out this pattern across opioids of the same class.
- Same timeline, different context: Heroin withdrawal is usually a single-substance problem. Codeine withdrawal is often complicated by the paracetamol in combination products and by other substances taken alongside it.
- Uncomfortable, not usually dangerous alone: Opioid withdrawal is intensely unpleasant but rarely life-threatening by itself, which is why so many attempt it unsupervised and return to use when the post-acute phase arrives without support.
- Managed as any opioid: Jintara treats codeine withdrawal through opioid detox with 24/7 nursing, not as a lesser problem because the drug came from a pharmacy.
A medically supervised taper makes the process safer and far more survivable as a decision, which is the difference between white-knuckling and completing.
“A detox alone does not deal with the why. Most people who do detox end up relapsing pretty quickly because they haven't dealt with the reasons they're self-medicating.
Codeine Is Rarely Used Alone.
By the time codeine dependence reaches treatment, it is often not the only thing in the picture. Codeine is commonly combined with alcohol, and sometimes with benzodiazepines or sleep medication, each of which depresses the central nervous system through its own pathway. Stacking depressants compounds the risk to breathing and complicates both the detox and the reasons behind the use.
- Something usually started it: Many people who develop codeine dependence began using against pain that was real, or against anxiety, low mood, or poor sleep that was never properly assessed.
- Treating one and not the other fails: Managing the opioid while ignoring the condition underneath leaves the driver of use intact. Jintara's dual diagnosis treatment addresses both together.
- Every substance mapped first: The psychiatric assessment on admission records everything in play before the taper is designed, because a taper built on half the picture is unsafe.
The chemistry can be managed in a week or two. The reasons a person reached for codeine take the length of the program to address.
How Jintara Treats Codeine Dependence.
Jintara's approach to codeine starts from the same foundation as its heroin and prescription-opioid care, because the underlying mechanism is identical. On admission, the psychiatrist assesses substance history, duration, the exact formulation used, any combination-product liver risk, and any co-occurring conditions. A medically supervised opioid taper manages the acute phase, dosed to the individual and monitored by 24/7 nursing.
The medical work does not happen in isolation. The 30-day treatment program runs detox and therapy together, so a client in the early days of withdrawal is already beginning the work that addresses why the use started. Assessment, nursing, and the day-two hospital workup are included in the program cost.
- Psychiatrist-led taper: Lertkhwan Sukpia oversees the opioid detox protocols, adjusting the taper to each person's pattern and metabolism.
- Liver screening as standard: The day-two workup catches combination-product organ effects rather than leaving them to chance.
- One connected team: Nursing, psychiatry, and therapy work from a single plan in a facility that treats a maximum of 10 clients at a time.
Codeine Cough Syrup, Lean, and Purple Drank.
One codeine pattern deserves its own attention: prescription cough syrup mixed with soft drink and often alcohol, known on the street as lean or purple drank. That preparation combines codeine with an antihistamine called promethazine, which deepens the sedation and sharply raises the overdose risk, and it tends to affect a younger group than other codeine presentations.
- A distinct pharmacology: Because the mechanism and the risks differ, Jintara covers it in full on a dedicated page about codeine cough syrup abuse.
- Same clinical foundation: The treatment rests on the same opioid use disorder protocol described here, applied to that specific preparation.
- If that is the pattern: The sub-page addresses the promethazine mechanism, the role of alcohol, and how the combination is managed in detox.
Lean is a codeine problem with an extra layer, and it is treated as one.
Detox Alone Does Not Resolve Codeine Addiction.
The end of physical withdrawal is not the end of addiction. Detox manages the acute and post-acute phases of dependence. It does not touch the reason a person started using codeine: the pain that was never resolved, the anxiety that was never treated, the sleep that never came, or the circumstances that made a pharmacy opioid feel necessary.
- Not a standalone service: Jintara does not offer detox on its own. Mental health treatment runs alongside the medical detox from the first week.
- Therapy starts early: Individual sessions, group work, and trauma-focused therapy are available from week one, matched to each client's clinical stability.
- The harder half decides the outcome: The pharmacology is the easier problem. The reasons behind the use are the half that determines whether recovery holds.
If codeine is where your search started, Jintara is a small adult residential program in Chiang Mai built to treat it properly.
Talk with Our Admissions Team
Common Questions About Codeine Addiction Treatment
Yes. Codeine is converted to morphine in the body, so codeine dependence is opioid dependence at the receptor level. The withdrawal syndrome, the tolerance pattern, and the treatment protocol are the same as for other opioids. The main difference is that codeine is often prescribed or sold over the counter, so dependence tends to start legally and go unrecognised for longer.
Yes. Any opioid used regularly produces tolerance and physical dependence, and codeine is an opioid. Many people who develop codeine dependence began with a legitimate prescription or an over-the-counter product, then found the same dose no longer worked. The legal origin of the drug does not protect against addiction.
Combination products like co-codamol pair codeine with paracetamol, also called acetaminophen, which is toxic to the liver in overdose. As someone escalates the dose to get the opioid effect, they also escalate their paracetamol intake, risking liver injury. Acetaminophen overdose causes roughly half of acute liver failure cases in the United States, which is why regulators capped the amount per dose and why Jintara screens the liver on admission.
The timeline is similar because both are short-acting opioids: symptoms begin within 8 to 24 hours and last roughly 4 to 10 days. The difference is context. Codeine withdrawal is more often complicated by the paracetamol in combination products and by other substances used alongside it, so the medical picture is frequently more complex even though the core symptoms match.
A liver enzyme called CYP2D6 controls how much codeine becomes morphine, and people carry different genetic versions of it. Ultra-rapid metabolisers convert codeine to morphine faster, so an ordinary dose produces a larger opioid effect and a higher dependence risk. This genetic variation is one reason a codeine taper has to be individualised rather than run from a fixed chart.
In most cases of daily dependence, yes. Codeine produces full opioid dependence, and withdrawal follows an opioid timeline. A medically supervised taper with nursing makes the process safer and significantly reduces the chance of leaving treatment before it is complete. It also allows the liver risk from combination products to be assessed and managed at the same time.
Independently Verified
Jintara is accredited against Thailand’s national quality standard for drug treatment and rehabilitation facilities, jointly certified by the Healthcare Accreditation Institute, the body that accredits Thailand’s hospitals, with the Princess Mother National Institute on Drug Abuse Treatment and the Department of Medical Services, Ministry of Public Health. Certificate no. 25/2569, valid 20 May 2026 to 19 May 2029.